Clinical Trials · NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 142
- Start date
- Jan 2025
- Locations
- 54 sites, 7 countries
- Primary endpoint
- Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)